SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Mike McFarland who wrote (44)7/4/2006 9:42:29 PM
From: Mike McFarland  Respond to of 210
 
Bauer and Fletcher presented a preclinical evaluation of IPI-504 in GIST cell lines at the joint National Cancer Institute-American Association of Cancer Researchers-European Organization for Research and Treatment of Cancer meeting on targeted therapies held Nov. 14-18 in Philadelphia, PA, showing that IPI-504 is as effective as 17-AAG at shutting down Gleevec-resistant GIST.

liferaftgroup.org